High cure rates in smear-positive tuberculosis patients using ambulatory treatment with once-weekly supervision during the intensive phase in Sulawesi, Republic of Indonesia

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 12, 1999, Pages 1066-1072

  Becx Bleumink, M ^a,b   Djamaluddin, S ^b   Loprang, F ^c   De Soldenhoff, R ^d   Wibowo, H ^b   Aryono, M ^e  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^b Communic Dis Contr South Sulawesi ^*  (Netherlands)

^c World Health Organization Indonesia   (Indonesia)

^d Netherlands Leprosy Relief Assoc   (Indonesia)

^e TB/Leprosy Provincial Health Office   (Indonesia)

Author keywords

DOTS strategy; Pilot projects; Treatment outcome; Tuberculosis control; Weekly supervision

Indexed keywords

ARTICLE; HEALTH CARE POLICY; HUMAN; INDONESIA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; RELAPSE; SPUTUM SMEAR; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

AMBULATORY CARE; COMMUNICABLE DISEASE CONTROL; HUMANS; INDONESIA; PILOT PROJECTS; SPECIMEN HANDLING; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0032720442     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Indonesia-World Health Organization. Joint evaluation of the National Tuberculosis Programme. Geneva, Switzerland: WHO, 1994.
2. Pedoman Penyakit Tuberkulosis. Manual for the pilot projects in Sulawesi. Depkes RI (Ministry of Health). Indonesia: Netherlands Leprosy Relief Association and KNCV, 1993.
3. International Union Against Tuberculosis and Lung Disease. Tuberculosis guide for high prevalence countries. 2nd ed. Paris, France: IUATLD 1992.
4. World Health Organization. TB, a global emergency. WHO report on the TB epidemic. WHO/TB/94.177. Geneva Switzerland: WHO, 1994.
5. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva, Switzerland: WHO, 1993.
6. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Geneva Switzerland: WHO, 1997.
7. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981: 171-174.
8. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991; 143: 707-712.
9. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Tubercle 1982; 63: 89-98.
10. East and Central African/British Medical Research Council Fifth Collaborative Study. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tubercle 1986; 67: 5-15.
11. Hong Kong Chest Service/British Medical Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle 1979; 60: 201-210.
12. Algerian Working Group/British Research Council Cooperative Study. Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Tubercle 1991; 72: 88-100.
13. Feng-Zeng Z, Levy M H, Sumin W. Sputum microscopy results at two and three months predict outcome of tuberculosis treatment. Int J Tuberc Lung Dis 1997; 1: 570-572.
14. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347: 358-362.
15. Westaway M S, Conradie P W, Remmers L. Supervised outpatient treatment of tuberculosis: evaluation of a South African rural programme. Tubercle 1991; 72: 140-144.
16. Chum H J. Ten years of the National Tuberculosis/Leprosy Programme in Tanzania. Bul Int Union Tuberc Lung Dis 1988; 64(3): 34-36.
17. Neher A, Breyer G, Shrestha B, Feldmann K. Directly observed intermittent short-course chemotherapy in the Kathmandu valley. Tubercle Lung Dis 1996; 77: 302-307.
18. Kumaresan J A, Ahsan Ali A K Md, Parkkali L M. Tuberculosis control in Bangladesh: success of the DOTS strategy. Int J Tuberc Lung Dis 1998; 2: 992-998.
19. Tam C M, Chan S L, Lam C W, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med 1998; 157: 1726-1733.
20. O'Brien R J, Vernon A A. New tuberculosis drug development: how can we do better. Am J Respir Crit Care Med 1998; 157: 1705-1707.
21. Tam C M, Chan S L, Lam C W, Dickinson J M, Mitchison D A. Unavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997; 1: 411-416.
22. Becx-Bleumink M, Broekmans J F. Editorial. Tuberculosis: where do we stand? Trop Med Int Health 1998; 3: 423-424.